2025 Equity Plan Proposals: Continued Robust Shareholder Support

Key Takeaways

• 25% of Russell 3000 filed equity-plan proposals in 2025.
• Average shareholder support remained high at 88%.
• Proxy‑advisor opposition cuts support ~16 points (ISS) or 11 (GL).
• Health‑care sector accounts for half of failed proposals.
• Companies vote every 2‑3 years; utilities about every 4 years.

Summary

In 2025, roughly one‑quarter of Russell 3000 companies submitted equity‑plan proposals, mirroring 2023‑2024 activity. Shareholder backing stayed strong, averaging 88% approval, with fewer than half a percent of proposals failing. Proxy‑advisor opposition, especially from ISS, reduced support by about 16 percentage points, yet failure rates rose only modestly. The health‑care sector represented about half of the rare unsuccessful votes.

Pulse Analysis

S. firms, with about 25 % of the Russell 3000 filing such motions each year. The consistency of this cadence—typically every two to three years for most sectors—reflects the ongoing need to replenish share reserves for stock‑option and restricted‑stock programs that attract and retain talent. Despite the frequency, shareholder sentiment remains overwhelmingly positive, as evidenced by an 88 % average approval rate in 2025.

This stability suggests that investors view well‑structured equity plans as a net benefit to company performance rather than a source of undue dilution. Proxy‑advisor recommendations, however, still wield measurable influence. Institutional Shareholder Services (ISS) issued favorable guidance for 67 % of proposals, while Glass Lewis did so for 87 %, and opposition from either firm trimmed support by roughly 16 and 11 percentage points respectively. Certain industries—communication services, health‑care, information technology, consumer discretionary, and real estate—experience higher rates of advisor dissent, potentially due to perceived dilution risk or less transparent plan design. Nonetheless, the overall failure rate remains low, rising only to about 3 % when both advisors oppose, underscoring the limited but strategic power of these endorsements.

To preserve high approval odds, issuers should adopt a data‑driven approach to share‑reserve modeling, quantifying dilution under multiple price scenarios and benchmarking against peers. Early engagement with the largest institutional holders, coupled with clear disclosure of shareholder‑friendly features such as caps on dilution or optional cash buyouts, can preempt adverse proxy recommendations. Aligning plan parameters with known bright‑line policies—especially those concerning dilution thresholds—further mitigates risk. Companies that integrate these practices not only improve vote outcomes but also reinforce investor trust in their compensation governance framework.